trial

Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

NCTId NCT00337662
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 628 (actual)
Sponsored by Eli Lilly and Company
Primary completion 2007-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
628 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2006-05
Primary completion
2007-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
OlanzapineRisperidone

Sponsors

Eli Lilly and CompanyLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

34 total
Little Rock, United StatesEscondido, United StatesGarden Grove, United StatesGlendale, United StatesNational City, United StatesOrange, United StatesSan Diego, United StatesSanta Ana, United StatesWashington D.C., United StatesFort Lauderdale, United StatesHialeah, United StatesChicago, United States

Facts & assertions

4 sourced
Enrollment
628
Phase
PHASE4
Primary Completion Date
2007-12
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
Risperidone
drug
lead_sponsor
Eli Lilly and Company
company
indication
Schizophreniform Disorder
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person